Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bright Minds Biosciences Inc. - common stock (NQ: DRUG )

32.38 -0.29 (-0.89%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bright Minds Biosciences Inc. - common stock

< Previous 1 2 3 4 5 Next >
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
From Bright Minds Biosciences
Via GlobeNewswire
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month
The reason for the stock's rapid ascent is a mystery. 
Via The Motley Fool
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
From Bright Minds Biosciences
Via GlobeNewswire
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10. 
Via Benzinga
Topics Government
Exposures Political
What's Going On With Bright Minds Biosciences Stock?
Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday announced a new collaboration with brain health-focused AI company Firefly... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
From Bright Minds Biosciences
Via GlobeNewswire
MarketBeat Week in Review – 10/14 - 10/18
Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election. 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Crude Oil Down Over 1%; American Express Shares Fall After Q3 Results
Via Benzinga
Exposures Fossil Fuels
What's Going On With Bright Minds Biosciences Stock Friday?
Bright Minds Biosciences shares are moving higher on Friday. The company announced a $35 million non-brokered private placement. 
Via Benzinga
Dow Falls Over 100 Points; Netflix Posts Upbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis
Firefly Neuroscience partners with Bright Minds Biosciences to analyze positive Phase 1 data of BMB-101 using advanced AI technology, setting the stage for Phase 2 trials. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF
Via AB Newswire
Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
From Bright Minds Biosciences
Via GlobeNewswire
US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results
Via Benzinga
Bright Minds Biosciences Stock Surges Almost 1,500%
Bright Minds Biosciences (NASDAQ: DRUG) soared 1,445% in a single day, trading over 100 million shares without any news. 
Via MarketBeat
Why Ericsson Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
From Bright Minds Biosciences
Via GlobeNewswire
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
From Bright Minds Biosciences
Via GlobeNewswire
Bright Minds Biosciences Reports Improved Financial Position For Q3 Amid Ongoing R&D Efforts
Bright Minds Biosciences reports a significant reduction in net losses for Q3 2024 while advancing its R&D programs focused on serotonergic therapies for CNS disorders. 
Via Benzinga
DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q3 2024
Bright Minds Biosciences just reported results for the third quarter of 2024. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today! 
Via InvestorPlace
DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024
Bright Minds Biosciences just reported results for the second quarter of 2024. 
Via InvestorPlace
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Exposures Interest Rates
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Via Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Via Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Via Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.